Prota Therapeutics is focused on developing innovative oral immunotherapy treatments for food allergies, particularly peanut allergies. Their lead investigational product, PRT120, aims to induce sustained unresponsiveness, or remission, in patients with peanut allergies. This approach is based on over two decades of research led by Professor Mimi Tang and seeks to provide long-lasting protection from allergic reactions, allowing individuals to consume peanuts freely without ongoing treatment. The technology behind PRT120 is designed to promote significant immune changes that redirect the body’s response from an allergic reaction to tolerance, thereby reducing allergen-specific IgE levels.

The therapeutic goals of Prota's PRT120 include achieving desensitization and sustained unresponsiveness. Desensitization offers temporary protection during active treatment, while sustained unresponsiveness signifies a lasting absence of clinical reactivity even after treatment has ceased. This long-term outcome is assessed through food challenges conducted after a period of allergen avoidance, demonstrating the potential for patients to maintain tolerance to peanuts. Prota Therapeutics is committed to advancing this novel approach to allergen immunotherapy, with the ultimate aim of improving the quality of life for individuals suffering from food allergies.

Australia

Prota Therapeutics is an Australian biotech company established in 2016, dedicated to developing and commercializing cutting-edge oral immunotherapy treatments for food allergies. They have achieved significant quality of life improvements and clinical remission of peanut allergy in pediatric patients, with a 51 percent peanut allergy remission rate. The company has also secured a $21 million financing led by SPRIM Global Investments.

Prota Therapeutics

Company Details